PharmaLex Group acquired Generational Equity client, Safis Solutions LLC on April 7, 2017. Details were not disclosed.

Safis Solutions, headquartered in Indianapolis, Indiana, assists pharmaceutical, medical device and biotech companies around the globe in gaining and retaining product approvals with regulatory bodies in the U.S. and internationally. 

“We are delighted to be joining the PharmaLex Group,” said Safis Solutions founder Ping Poulsen. “Not only can we expand our breadth and depth of expertise by being part of a global multinational company but a more mature infrastructure will allow us to offer our clients a more comprehensive service portfolio.”

PharmaLex, headquartered in Frankfurt, Germany, provides solutions for drug development, regulatory affairs, and pharmacovigilance. The company features a multidisciplinary team from more than 40 nationalities with knowledge that spans the whole spectrum of life sciences, including biology, biochemistry, pharmacology, engineering, food chemistry, medicine, nutritional science, pharmacy science, toxicology and veterinary medicine.

“The acquisition enables PharmaLex to complement its existing E.U. medical device expertise with high quality and established U.S. medical device capabilities,” said Dr. Thomas Dobmeyer, PharmaLex CEO. “It will help establish us as a key provider in the U.S.”

Generational Equity Managing Director Douglas Smith and Vice President Ryan Johnson led the deal to a successful close.

“It was very important to Ping Poulsen that Safis Solutions be acquired by a company best able to leverage Safis’ expertise and maintain its reputation in major medical and pharmaceutical markets for exceptional ethical and work standards,” said lead dealmaker Johnson. “PharmaLex was the perfect fit and offers an exciting opportunity for Safis’ employees to be part of a larger multinational company.”